Douglas J. Swirsky

Companies

• Barinthus Biotherapeutics plc.Principal Accounting Officer May 1, 2026 to now¹
• Cellectar Biosciences, Inc.Board member Apr 18, 2017 to now²
• MaxCyte (United States)Chief financial officer Mar 28, 2023 to Apr 10, 2026³
• MetaVia Inc.Board member Sep 3, 2020 to Sep 3, 2020⁴
• Opus Genetics, Inc.Board member Nov 16, 2018 to Jan 30, 2019⁵
• Opus Genetics, Inc.Chief executive officer Nov 16, 2018 to Jan 30, 2019⁵
• Opus Genetics, Inc.President Jan 4, 2018 to Jan 30, 2019⁶
• Pernix Therapeutics HoldingsBoard member Nov 17, 2017 to May 23, 2018⁷
• Opus Genetics, Inc.Chief financial officer Jan 4, 2018 to Jan 4, 2018⁶
• GenVecBoard member Sep 5, 2013 to Jun 20, 2017⁸
• GenVecChief executive officer Sep 5, 2013 to Jun 20, 2017⁸
• GenVecPresident Sep 5, 2013 to Jun 20, 2017⁸
• GenVecChief financial officer Sep 19, 2006 to Jan 24, 2013⁹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• MUMaxCyte (United States) MXCT151,669 shares¹⁰$197.2K at $1.30Mar 17, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Mar 17, 2026Sold 10,142 shares at $0.82 of MaxCyte (United States)¹⁰
• Aug 13, 2025Bought 50,000 shares at $1.29 of MaxCyte (United States)¹¹
• Mar 18, 2025Sold 6,939 shares at $3.18 of MaxCyte (United States)¹²
• Mar 14, 2025Granted 37,500 shares of MaxCyte (United States)¹³
• Mar 15, 2024Granted 81,250 shares of MaxCyte (United States)¹⁴